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Abstract The involvement of protein kinases was studied in mu
opioid receptor activation of mitogen-activated protein (MAP)
kinase using cells transfected with the receptor clone. The
cAMP/protein kinase A (PKA) pathway is known to be the
major biochemical pathway for mu opioid receptor signaling.
However, our data showed that stimulating adenylyl cyclase or
activating PKA had no effect on mu receptor enhancement of
MAP kinase activity, suggesting that the cAMP/PKA pathway
is not involved in mediating the mu receptor activation of MAP
kinase. Inhibition of phosphatidylinositol (PI) 3-kinase reduced
mu receptor enhancement of MAP kinase activity, suggesting PI
3-kinase involvement. Together, these results show that cross-
talk between the mu opioid receptor and the MAP kinase
cascade is not mediated by the cAMP/PKA pathway, but
involves PI 3-kinase.
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1. Introduction
Mitogen-activated protein (MAP) kinases are serine/threo-
nine kinases that play an important role in the regulation of
cell growth and di¡erentiation. They are activated by growth
factor receptors and other tyrosine kinase receptors and they
in turn activate various regulatory molecules in the cytoplasm
and in the nucleus [1^3]. They have also been shown to be
activated by G protein-coupled receptors. A number of pro-
tein kinases, including protein kinase A (PKA), protein kinase
C (PKC) and protein tyrosine kinase (PTK), are known to be
involved in the mechanism by which G protein-coupled recep-
tors stimulate MAP kinase activity [1,4^6]. More recently,
phosphatidylinositol (PI) 3-kinase has been reported to par-
ticipate in G protein-coupled receptor activation of MAP ki-
nase [7,8], further implicating the complexity of protein kinase
involvement in mediating the cross-talk between G protein-
coupled receptors and the MAP kinase cascade.
Opioids are some of the most e¡ective pain-relieving drugs
used in the clinical management of pain [9^11]. In addition to
their analgesic e¡ect, opioid peptides and alkaloids also a¡ect
a number of physiological functions including hormone secre-
tion, neurotransmitter release, feeding, gastrointestinal motil-
ity and respiratory activity [12]. Opioids achieve their e¡ects
by activating three types of membrane-bound receptors, mu,
delta and kappa [10,13], of which the mu opioid receptor is
the major site for commonly used opioid narcotica, including
both naturally existing drugs such as morphine and codeine as
well as synthetic compounds such as fentanyl and methadone.
The mu opioid receptor is a member of the G protein-
coupled receptor family [14,15]. At the cellular level, it exerts
two types of e¡ects: a decrease in the intracellular level of
cAMP by inhibiting adenylyl cyclase (AC) activity [16,17]
and reduction of the neuronal excitability by inhibiting Ca2
channels and activating K channels [18]. These cellular ef-
fects induced by mu opioid receptor have been shown to be
modulated by protein kinases, including PKA, PKC and
Ca2/calmodulin-dependent protein kinase II [19].
The mu opioid receptor has recently been shown to activate
MAP kinase [20,21], involving the activity of both PTK and
PKC [21]. However, the pathway by which the mu opioid
receptor cross-talks with the MAP kinase is not clear. In
particular, it is of interest to determine whether the cAMP/
PKA pathway is involved, since it is the major second mes-
senger pathway for the mu opioid receptor [17], and the
cloned mu opioid receptor has been shown to couple to the
cAMP/PKA pathway either in transiently transfected COS
cells [14] or in stably transfected Chinese hamster ovary
(CHO) cells [22]. We sought to address this question in this
study.
2. Materials and methods
2.1. Cell culture
CHO-K1 cells were stably transfected with the rat mu opioid re-
ceptor as previously described [22]. The stably transfected cells (des-
ignated as CHO-K1 W18) were cultured in Ham’s F-12 medium (Gib-
co BRL, Baltimore, MD, USA) supplemented with 10% fetal bovine
serum (Hyclone Laboratories, Logan, UT, USA) in a humidi¢ed at-
mosphere consisting of 5% CO2 and 95% air at 37‡C.
2.2. MAP kinase activity assay
Cells were grown to subcon£uence in 100 mm diameter dishes,
serum-free starved overnight (V12 h) and incubated with the indi-
cated compounds for the indicated time at 37‡C. Cells were then
washed three times with ice-cold PBS, scraped into 0.5 ml of ice-
cold lysis bu¡er (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 15 mM
NaF, 5 mM EDTA, 2 mM DTT, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl £uoride and 10 Wg/ml leupeptin and 10 Wg/ml
aprotinin) and homogenized with a Dounce homogenizer (20^30
strokes). The homogenate was centrifuged at 50 000Ug for 20 min
and the supernatant was assayed for MAP kinase activity, using the
p42/p44 MAP kinase enzyme assay system (Amersham, Buckingham-
shire, UK). Protein concentrations of cell lysate were determined by
the method of Bradford [23]. All data are shown as mean þ S.E.M.
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3. Results
3.1. Mu opioid receptor-mediated MAP kinase activation
To examine mu opioid receptor-mediated activation of
MAP kinase activity, we used CHO-K1 W18 cells that have
been stably transfected with a cloned mu opioid receptor
cDNA [22]. For agonists, we utilized both morphine, the plant
alkaloid agonist from opium that displays relative selectivity
for the mu opioid receptor over other types of opioid recep-
tors [10,24], and endomorphine-1, a recently discovered en-
dogenous peptide that displays high a⁄nity and selectivity
for the mu opioid receptor [25] with full agonist activity
[26]. Both agonists increased MAP kinase activity over the
non-stimulated control level (Fig. 1A) and the stimulatory
e¡ects by both agonists were completely blocked by the opioid
antagonist naloxone (Fig. 1A). In CHO cells not transfected
with the mu opioid receptor, these opioid agonists had no
e¡ect on the level of MAP kinase activity (data not shown).
MAP kinase activation was rapid and transient, with the in-
crease of MAP kinase activity peaking at about 5 min after
the agonist addition before declining toward the baseline level
(Fig. 1B). Both endomorphine-1 and morphine showed con-
centration-dependent stimulation of MAP kinase activation as
indicated by their dose-response curves (Fig. 1C). By compar-
ison, endomorphine-1 appeared more potent in stimulating
MAP kinase than morphine, with a lower EC50 value
(20 nM) than that of morphine (80 nM).
3.2. Mu opioid receptor activation of MAP kinase cascade
involves a pathway distinct from the cAMP/PKA pathway
In the MAP kinase cascade, MEK, a MAP kinase kinase, is
the major activator of MAP kinase activity by tyrosine and
threonine phosphorylation of MAP kinases [5]. To verify that
the mu opioid receptor activation of MAP kinase activity is
mediated by MEK, we used a MEK inhibitor, PD98059 [27],
and examined mu receptor-induced MAP kinase activation.
As shown in Fig. 2A, the MEK inhibitor PD98059 completely
blocked the MAP kinase activation by endomorphine-1, con-
¢rming that MEK indeed mediates the mu opioid receptor
activation of MAP kinase.
At the cellular level, opioid receptors decrease AC activity,
resulting in reduced cAMP levels [17]. The cloned mu opioid
receptor has also been shown to negatively couple to the
cAMP/AC pathway either in transiently transfected COS cells
Fig. 1. MAP kinase activation by the mu opioid receptor. (A) Cells were incubated with 500 nM endomorphine-1 or 1 WM morphine for 5 min,
with or without 10 WM naloxone. #: Signi¢cantly di¡erent from control. NS: not signi¢cantly di¡erent from control. (B) Transient activation
of MAP kinase by the mu receptor. Cells were treated with 500 nM endomorphine-1 for the indicated time intervals. (C) Dose-response rela-
tions of mu opioid receptor-mediated MAP kinase activation. Cells were stimulated for 5 min by the mu opioid receptor agonists morphine
(top panel) or endomorphine-1 (bottom panel) at the indicated concentrations (in molar). EC50 values are 80 nM for morphine and 20 nM for
endomorphine-1.
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[14] and in stably transfected CHO cells [22]. Thus, it is of
interest to determine whether the cAMP/PKA pathway is in-
volved in mu receptor-induced MAP kinase activation. As
shown in Fig. 2B, AC activator forskolin had little e¡ect on
the basal level of MAP kinase activity (forskolin data not
signi¢cantly di¡erent from the control) and it did not appear
to a¡ect mu receptor activation of MAP kinase (endomor-
phine-1+forskolin results not signi¢cantly di¡erent from the
endomorphine-1 alone results). Furthermore, 8-chlorophe-
nylthio-cAMP (8-CPT-cAMP), a membrane-permeable
cAMP analogue that can activate PKA, also had no in£uence
either on the basal MAP kinase activity (8-CPT-cAMP data
not signi¢cantly di¡erent from the control) or on mu receptor-
induced MAP kinase activity (endomorphine-1+8-CPT-cAMP
results not signi¢cantly di¡erent from the endomorphine-1
alone results). These results indicate that activating the
cAMP/PKA pathway neither alters basal MAP kinase activity
nor interferes with mu receptor enhancement of MAP kinase
activity. These results therefore suggest that the cAMP/PKA
pathway is not involved in mediating the mu opioid receptor
activation of MAP kinase. In other words, mu receptor acti-
vation of MAP kinase involves a signaling pathway distinct
from receptor inhibition of the cAMP/PKA pathway.
3.3. PTK and PKC modulate both basal and receptor-activated
MAP kinase activity
Fukuda et al. reported that both genistein, a PTK inhibitor,
and GF109203X, a PKC inhibitor, were able to reduce opioid
receptor-mediated MAP kinase activation [21]. Using these
two protein kinase inhibitors, we con¢rmed the results of
Fukuda et al. in our CHO-K1 W18 cells (Fig. 3A, right-hand
two bars: endomorphine-1+genistein results signi¢cantly dif-
ferent from endomorphine-1 alone results ; Fig. 3B, right-hand
two bars: endomorphine-1+GF109203X results signi¢cantly
di¡erent from endomorphine-1 alone results). Moreover, we
observed that without activating the mu opioid receptor, the
basal activity of MAP kinase (control) was also signi¢cantly
reduced by genistein (Fig. 3A, left-hand two bars) or
GF109203X (Fig. 3B, left-hand two bars). These results sug-
gest that there is a basal level of endogenous PTK and PKC
activity in these cells to stimulate MAP kinase activity, which
can be blocked by their respective inhibitors.
3.4. PI 3-kinase is involved in mu opioid receptor activation of
MAP kinase
It was recently reported that PI 3-kinase can mediate cer-
Fig. 2. Mu opioid receptor stimulation of MAP kinase activity in-
volves a pathway distinct from the cAMP/PKA pathway. (A) MEK
involvement. Cells were incubated for 5 min with 500 nM endomor-
phine-1 with or without 15 min pretreatment of the MEK inhibitor
PD98059 (100 WM). *: Signi¢cantly di¡erent (P6 0.05), NS: not
signi¢cantly di¡erent. (B) The cAMP/PKA pathway is not involved.
Cells were stimulated for 5 min with 500 nM endomorphine-1 with
or without 10 min pretreatment of either the AC activator forskolin
(30 WM) or the cAMP analogue 8-CPT-cAMP (1 mM).
Fig. 3. Both basal- and receptor-mediated MAP kinase activation
are modulated by PTK and PKC. (A) PTK e¡ect. Cells were
treated with PTK inhibitor genistein (20 WM, 2 h pretreatment)
alone or with genistein plus endomorphine-1 (500 nM, 5 min). (B)
PKC e¡ect. Cells were incubated with PKC inhibitor GF109203X
(1 WM, 4 h pretreatment) alone or with GF109203X plus endomor-
phine-1 (500 nM, 5 min). *: Signi¢cantly di¡erent (P6 0.05).
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tain G protein-coupled receptor activation of the MAP kinase
signaling pathway [7,8] and that such linkage is provided by
GLQ subunits [8]. To examine whether PI 3-kinase is involved
in mediating the mu receptor e¡ect, we employed two struc-
turally distinct inhibitors of PI 3-kinase, wortmannin [28] and
LY294002 [29]. We observed that both wortmannin and
LY294002 reduced mu opioid receptor-induced MAP kinase
activation (Fig. 4). Compared with endomorphine-1 alone
treatment, MAP kinase activity for either endomorphine-
1+wortmannin treatment or endomorphine-1+LY294002
treatment was signi¢cantly decreased. These results indicate
that PI 3-kinase is involved in mu opioid receptor activation
of MAP kinase. Moreover, either wortmannin or LY294002
alone inhibited the endogenous MAP kinase activity (Fig. 4,
data for wortmannin alone or LY294002 alone signi¢cantly
di¡erent from untreated control), suggesting that PI 3-kinase
may exert a basal level activation on the MAP kinase.
3.5. Multiple kinase modulation in a parallel fashion
Since MAP kinase activation by mu opioid receptor was
not completely blocked by the inhibition of any one of the
three kinases PTK (Fig. 3A), PKC (Fig. 3B) or PI 3-kinase
(Fig. 4), we tested combined inhibition of two kinases. The
results are summarized in Table 1. Upon mu receptor activa-
tion of MAP kinase, combined inhibition of PTK and PKC
with genistein plus GF109203X (End+Ge+GF) brought the
MAP kinase level to below the untreated control (85% of
control), combined inhibition of PTK and PI 3-kinase with
genistein plus wortmannin (End+Ge+Wor) resulted in a re-
duction to 77% of control and combined inhibition of PKC
and PI 3-kinase (End+GF+Wor) yielded 72% of control. In
addition, inhibition of any two kinases alone, without endo-
morphine stimulation of the mu opioid receptor, resulted in a
signi¢cant reduction of the basal level of MAP kinase activity
(Ge+GF at 61% of control, Ge+Wor at 49% of control and
GF+Wor at 56% of control). Furthermore, inhibition of all
three kinases also resulted in signi¢cant reduction of both
basal (Ge+GF+Wor at 47% of control) and endomorphine-
stimulated (End+Ge+GF+Wor at 88% compared to End
alone at 209%) MAP kinase activity (Table 1). Taken togeth-
er, these results suggest that the three kinases, PI 3-kinase,
PTK and PKC, all participate in modulating the MAP kinase
activity in these cells.
4. Discussion
The mu opioid receptor is the major cellular target of po-
tent opioid analgesics [10]. It mediates agonist e¡ects via G
protein coupling to cellular e¡ectors and cAMP/PKA is the
major biochemical pathway for mu opioid receptor signaling
[16,17]. It has been reported that stimulation of the mu opioid
receptor resulted in an increase in MAP kinase activity
[20,21]. However, the signal transduction pathway that leads
from stimulation of mu opioid receptor to MAP kinase acti-
vation is not clear. Since there is considerable evidence that
cAMP plays a role in the regulation of MAP kinase activity,
either inhibitory [30,31] or stimulatory [32,33], it would be of
interest to determine whether the cAMP/PKA pathway pro-
vides the link for mu receptor activation of MAP kinase ac-
tivity. Our results demonstrated that mu receptor stimulation
of MAP kinase activity was not in£uenced either by activating
AC with forskolin or by stimulation of protein kinase A with
a cAMP analogue (Fig. 2B). Thus, it appears that the cAMP/
PKA pathway is not involved in mu opioid receptor-mediated
MAP kinase activation in these cells.
For cross-talk from G protein-coupled receptors to the
MAP kinase signaling cascade, there has been evidence for
the involvement of a number of protein kinase pathways.
For instance, reports have suggested pathways both depend-
ent on and independent of the stimulation of PKC and ele-
vation of cytosolic Ca2 [34,35]. Also, PTKs mediating
growth factor e¡ects have been shown to be modulated by
heterotrimeric G protein subunits [1,36]. More recently, PI
3-kinase involvement in mediating the signaling from G pro-
tein-coupled receptors to the MAP kinase cascade has been
shown [7,8], suggesting additional complexity in the cross-talk
between the G protein pathway and the MAP kinase path-
way. Our results suggest that PI 3-kinase is involved in medi-
ating the mu opioid receptor activation of MAP kinase (Fig.
4), similar to the involvement of PKC and PTK [21]. More-
Fig. 4. PI 3-kinase is involved in mu opioid receptor enhancement
of MAP kinase activity. Cells were incubated either with a PI 3-ki-
nase inhibitor (100 nM wortmannin or 50 WM LY294002) for
30 min or with 500 nM endomorphine-1 for 5 min with or without
30 min pretreatment of the inhibitors. #: Signi¢cantly di¡erent
from endomorphine-1 treatment cells (P6 0.05), *: signi¢cantly
di¡erent from untreated (control) cells (P6 0.05).
Table 1
Multiple kinase modulation of MAP kinase activity
Treatment MAP kinase activity (% of control)
Untreated control 100 þ 9.7
End 209 þ 18
Ge+GF 60.7 þ 9.0
End+Ge+GF 85.0 þ 8.5
Ge+Wor 49.3 þ 4.7
End+Ge+Wor 76.7 þ 7.5
GF+Wor 55.7 þ 7.4
End+GF+Wor 71.7 þ 9.1
Ge+GF+Wor 47.4 þ 1.0
End+Ge+GF+Wor 88.6 þ 16.1
Cells were incubated at 37‡C in a humidi¢ed atmosphere with 5%
CO2 for 5 min with 500 nM endomorphine-1 with or without pre-
treatment of two di¡erent kinase inhibitors together: 20 WM genis-
tein (2 h), 1 WM GF109203X (4 h) and 100 nM wortmannin (30
min). The respective controls of double-kinase inhibitor treatment
alone were also included. MAP kinase activity is expressed as per-
centage of control. All results are signi¢cantly di¡erent from control
(P6 0.05). End: endomorphine-1, Ge: genistein, GF: GF109203X,
Wor: wortmannin.
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over, we observed that inhibitors for these three kinases, when
applied alone, could not completely block the MAP kinase
activation by mu opioid receptor (Figs. 3 and 4), suggesting
that these kinases may act in an additive manner to modulate
mu receptor enhancement of MAP kinase activity.
In summary, our results indicate that the mu opioid recep-
tor activates MAP kinase by a di¡erent pathway from its
coupling to the cAMP/PKA pathway. This raises the question
as to what extent, if any, the two pathways of the mu receptor
action may interact. In this regard, it is interesting to note
that because neurons are terminally di¡erentiated cells, ‘long-
term’ mechanisms involved in cell growth and proliferation
such as the MAP kinase pathway are not thought to play a
major role in the neuronal function. Traditionally, neuro-
transmitter receptors, including the mu opioid receptor, have
been viewed to exert ‘short-term’ actions on neurons, i.e.
modulating neuronal excitability by changing ion channel
conductances and by regulating the protein phosphorylation
status via kinases such as PKA. With the increasing evidence
that many neurotransmitter receptors do activate the MAP
kinase pathway, this view may need to be expanded. It is
plausible that activation of MAP kinase by these receptors
may result in altered cellular processes in the brain, either in
glia cells that do proliferate or in neurons to cause ‘set point’
changes in the cell physiological status.
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